Ruplizumab
Ruplizumab
Ruplizumab (pronunciation: roo-pli-zoo-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is a type of biologic therapy that targets specific proteins in the body to help control the immune system's response.
Etymology
The name "Ruplizumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-lizu-" does not have a specific meaning and is used to create a unique name.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells. They are used in cancer treatment and other therapies.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Biologic therapy: Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments.
See Also
External links
- Medical encyclopedia article on Ruplizumab
- Wikipedia's article - Ruplizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski